v3.26.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenues, net $ 35,121 $ 1,571 $ 36,563 $ 3,741
Cost of revenues 3,347 111 3,631 265
Research and development (includes $7,965 and $10,996 of share-based compensation expense for the three months ended September 30, 2026 and 2025 and $16,686 and $22,095 for the six months ended September 30, 2026 and September 30, 2025, respectively) 145,747 164,568 347,763 317,487
Selling, general and administrative (includes $71,332 and $70,825 of share-based compensation expense for the three months ended September 30, 2026 and 2025 and $145,953 and $141,904 for the six months ended September 30, 2026 and 2025, respectively) 154,076 143,125 319,603 277,144
Total operating expenses 303,170 307,804 670,997 594,896
Gain on litigation settlement 0 0 392 0
Loss from operations (268,049) (306,233) (634,042) (591,155)
Change in fair value of investments (60,292) (128,501) (96,929) (109,376)
Change in fair value of liability instruments 0 20,959 0 23,288
Interest income (41,612) (45,341) (78,534) (93,663)
Other expense, net 200 5,694 2,330 16,902
Loss from continuing operations before income taxes (166,345) (159,044) (460,909) (428,306)
Income tax (benefit) expense (13,371) 6,995 (17,329) 11,644
Loss from continuing operations, net of tax (152,974) (166,039) (443,580) (439,950)
Income from discontinued operations, net of tax 15,763 0 15,763 0
Net loss (137,211) (166,039) (427,817) (439,950)
Net income (loss) attributable to noncontrolling interests 54,408 (52,520) (46,361) (103,076)
Net loss attributable to Roivant Sciences Ltd. (191,619) (113,519) (381,456) (336,874)
Amounts attributable to Roivant Sciences Ltd.:        
Loss from continuing operations, net of tax (207,382) (113,519) (397,219) (336,874)
Income from discontinued operations, net of tax 15,763 0 15,763 0
Net loss attributable to Roivant Sciences Ltd. $ (191,619) $ (113,519) $ (381,456) $ (336,874)
Basic and diluted net loss per common share:        
Loss from continuing operations, net of tax - basic (in dollars per share) $ (0.29) $ (0.17) $ (0.55) $ (0.49)
Loss from continuing operations, net of tax - diluted (in dollars per share) (0.29) (0.17) (0.55) (0.49)
Income from discontinued operations, net of tax - basic (in dollars per share) 0.02 0 0.02 0
Income from discontinued operations, net of tax - diluted (in dollars per share) 0.02 0 0.02 0
Net loss per common share—basic (in dollars per share) (0.27) (0.17) (0.53) (0.49)
Net loss per common share— diluted (in dollars per share) $ (0.27) $ (0.17) $ (0.53) $ (0.49)
Weighted average shares outstanding—basic and diluted        
Weighted average shares outstanding - basic (in shares) 722,751,617 680,947,866 721,769,574 680,619,200
Weighted average shares outstanding - diluted (in shares) 722,751,617 680,947,866 721,769,574 680,619,200
Product revenue, net        
Revenues, net $ 30,969 $ 0 $ 30,969 $ 0
License, milestone and other revenue        
Revenues, net $ 4,152 $ 1,571 $ 5,594 $ 3,741